Chemical Structure and Receptor Profile
Danazol is a synthetic drug with a pronounced steroid structure. Chemically, it is a derivative of 17α-ethynyltestosterone. Despite its structural relationship to male sex hormones, its pharmacodynamic profile is unique. In the human body, it acts as a partial progestin receptor agonist.
It is important to emphasize that the molecule lacks absolute selectivity: in addition to interacting with progestin targets, it also demonstrates affinity for androgen and glucocorticoid receptors, which largely determines the complex nature of its systemic endocrine effects.
Mechanism of Action: Central Blockade
A key pharmacological feature of danazol is the clear separation of its central and peripheral effects. In the periphery, its intrinsic progestin activity is extremely low. Consequently, direct peripheral effects on target organs (such as the uterus or mammary glands) are virtually absent.
The primary site of action is within the central nervous system. The molecule rapidly crosses the blood-brain barrier (BBB). Once inside the brain tissue, the drug actively stimulates progestin receptors located in the hypothalamus and pituitary gland.
This stimulation triggers a neuroendocrine cascade via negative feedback:
- A marked suppression of hypothalamic gonadotropin-releasing hormone (GnRH) secretion (incretion).
- Subsequent downregulation of key anterior pituitary gonadotropins—follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
- This central inhibition results in a systemic reduction of sex hormone production.
- Ultimately, this leads to the reliable inhibition of proliferation of all hormone-dependent tissues in the body.
Pharmacokinetics and Administration
The drug is administered exclusively via the oral route. Following absorption in the gastrointestinal tract, it rapidly distributes to tissues, reaching its central targets.
A critical pharmacokinetic parameter is the half-life ($t_{1/2}$), which for this 17α-ethynyltestosterone derivative is only 1.5 hours. This short half-life requires strict adherence to dosing regimens to prevent sharp fluctuations in plasma concentration and to ensure continuous suppression of the hypothalamic-pituitary-ovarian axis.
Clinical Indications
The drug's ability to induce medical atrophy of hormone-dependent structures determines its clinical spectrum. In modern medical practice, primary indications include:
- Endometriosis and associated infertility. Suppression of FSH and LH secretion deprives endometriotic lesions of hormonal stimulation, halting their growth.
- Benign breast diseases. The drug demonstrates high efficacy in treating fibrocystic breast changes, macromastia, and gynecomastia.
- Primary menorrhagia. Prescribed to correct heavy menstrual bleeding.
- Hereditary angioedema. Used as a prophylactic agent to prevent acute attacks.
Adverse Effects and Contraindications
Interference with delicate neuroendocrine regulation inevitably carries the risk of adverse reactions. Side effects involve multiple systems:
- Central nervous system: patients frequently report headaches, dizziness, and nervousness.
- Gastrointestinal tract: therapy may be complicated by dyspepsia and hepatic dysfunction.
- Vascular system: vasomotor reactions such as "hot flashes" are characteristic, directly linked to the drug-induced decrease in sex hormone levels.
Prescribing the drug requires a thorough medical history, as strict contraindications exist. These include pregnancy, lactation, and porphyria.